Literature DB >> 2827898

Effects of interferon-gamma on the activation of human T lymphocytes.

J P Siegel1.   

Abstract

The role of interferon (IFN)-gamma in the activation of human T cells was investigated. Addition of IFN-gamma to mixed-lymphocyte cultures (MLC) augmented both the proliferation and the development of T-cell-mediated cytotoxicity. IFN-gamma also augmented the early expression on CD8+ but not CD4+ lymphocytes of IL-2 receptor alpha chain (Tac antigen) and Class II major histocompatibility antigen (HLA-DR). This effect synergized with that caused by interleukin 2 and was not observed with IFN-alpha. The addition of neutralizing antibody against IFN-gamma to MLC suppressed the development of cytotoxicity and proliferation and the expression of activation antigens on CD8+ cells. In experiments in which highly purified CD8+ T cells were activated with cell-free stimuli, IFN-gamma slightly but significantly augmented proliferation, antibody to IFN-gamma suppressed proliferation, and excess IFN-gamma reversed this suppression. It is concluded that (i) IFN-gamma augmented activation of T cells in human MLC, (ii) IFN-gamma exerted effects directly on T cells, and (iii) IFN-gamma preferentially augmented CD8+ cell activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827898     DOI: 10.1016/0008-8749(88)90109-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  20 in total

1.  Transduction of human hepatocellular carcinoma cells with human alpha-interferon gene via retroviral vector.

Authors:  Shu-Bing Qian; Shi-Shu Chen
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

2.  Modulation by gamma interferon of antiviral cell-mediated immune responses in vivo.

Authors:  O Utermöhlen; A Dangel; A Tárnok; F Lehmann-Grube
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  T-cell-mediated cytotoxicity against Mycobacterium antigen-pulsed autologous macrophages in leprosy patients.

Authors:  M C Sasiain; S de la Barrera; F Minnucci; R Valdez; M M de Elizalde de Bracco; L M Baliña
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

Review 4.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Authors:  Elise Alspach; Danielle M Lussier; Robert D Schreiber
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-03-01       Impact factor: 10.005

Review 5.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

6.  Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Effects of gamma interferon, tumor necrosis factor alpha, and interleukin-2 on infection and proliferation of Theileria parva-infected bovine lymphoblasts and production of interferon by parasitized cells.

Authors:  J C DeMartini; C L Baldwin
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

8.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

9.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

10.  Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.

Authors:  N Seo; Y Tokura; K Matsumoto; F Furukawa; M Takigawa
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.